2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

GLIOBLASTOMA: BIOLOGY, GENETICS AND BEHAVIOR
1. Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumours
of the Central Nervous System. 4th ed. Lyon: Intl. Agency for Research; 2007.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med.
2005;352:987-996.
3. Swanson KR, Bridge C, Murray JD, et al. Virtual and real brain tumors:
using mathematical modeling to quantify glioma growth and invasion. J Neurol
Sci. 2003;216:1-10.
4. Bellail AC, Hunter SB, Brat DJ, et al. Microregional extracellular matrix
heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell
Biol. 2004;36:1046-1069.
5. Gupta M, Djalilvand A, Brat DJ. Clarifying the diffuse gliomas: an
update on the morphologic features and markers that discriminate oligodendroglioma
from astrocytoma. Am J Clin Pathol. 2005;124:755-768.
6. Brat DJ, Prayson RA, Ryken TC, et al. Diagnosis of malignant glioma:
Role of neuropathology. J Neurooncol. 2008;89:287-311.
7. Giannini C, Scheithauer BW, Burger PC, et al. Cellular proliferation in
pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol. 1999;58:46-53.
8. Hsu DW, Louis DN, Efird JT, et al. Use of MIB-1 (Ki-67) immunoreactivity
in differentiating grade II and grade III gliomas. J Neuropathol Exp
Neurol. 1997;56:857-65.
9. Moskowitz SI, Jin T, Prayson RA. Role of MIB1 in predicting survival in
patients with glioblastomas. J Neurooncol. 2006;76:193-200.
10. Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms
associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma.
Lab Invest. 2004;84:397-405.
11. Rong Y, Durden DL, Van Meir EG, et al. “Pseudopalisading” necrosis in
glioblastoma: a familiar morphologic feature that links vascular pathology,
hypoxia, and angiogenesis. J Neuropathol Exp Neurol. 2006;65:529-539.
12. Brat DJ, Castellano-Sanchez AA, Hunter SB, et al. Pseudopalisades in
glioblastoma are hypoxic, express extracellular matrix proteases, and are
formed by an actively migrating cell population. Cancer Res. 2004;64:920-927.
13. Dong S, Nutt CL, Betensky RA, et al. Histology-based expression
profiling yields novel prognostic markers in human glioblastoma. J Neuropathol
Exp Neurol. 2005;64:948-955.
14. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression,
and growth in tumors mediated by angiopoietins and VEGF. Science.
1999;284:1994-1998.
15. Tehrani M, Friedman T, Olson JJ, et al. Intravascular thrombosis in
central nervous system malignancies: a potential role in astrocytoma progression
to glioblastoma. Brain Pathol. 2008;18:164-171.
16. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular
permeability factor that promotes accumulation of ascites fluid. Science.
1983;219:983-985.
REFERENCES
17. Plate KH. Mechanisms of angiogenesis in the brain. J Neuropathol Exp
Neurol. 1999;58:313-320.
18. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its
receptors in gliomagenesis and tumoral angiogenesis. Neuro-oncol. 2005;7:
122-133.
19. Straume O, Chappuis PO, Salvesen HB, et al. Prognostic importance of
glomeruloid microvascular proliferation indicates an aggressive angiogenic
phenotype in human cancers. Cancer Res. 2002;62:6808-6811.
20. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy
plus radiotherapy compared with radiotherapy alone for pure and mixed
anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group
Trial 9402. J Clin Oncol. 2006;24:2707-2714.
21. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion
regions on 1p and 19q in human gliomas and their association with histological
subtype. Oncogene. 1999;18:4144-4152.
22. Perry A, Fuller CE, Banerjee R, et al. Ancillary FISH analysis for 1p
and 19q status: preliminary observations in 287 gliomas and oligodendroglioma
mimics. Front Biosci. 2003;8:a1-a9.
23. Brat DJ, Seiferheld WF, Perry A, et al. Analysis of 1p, 19q, 9p, and 10q
as prognostic markers for high-grade astrocytomas using fluorescence in situ
hybridization on tissue microarrays from Radiation Therapy Oncology Group
trials. Neuro-oncol. 2004;6:96-103.
24. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of
the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med.
2005;353:2012-2024.
25. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and
benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-
1003.
26. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of
human glioblastoma multiforme. Science. 2008;321:1807-1812.
27. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas.
N Engl J Med. 2009;360:765-773.
28. Capper D, Weissert S, Balss J, et al. Characterization of R132H
mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol.
2010;20:245-254.
29. The Cancer Genome Atlas Network. Comprehensive genomic characterization
defines human glioblastoma genes and core pathways. Nature.
2008;455:1061-1068.
30. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic
analysis identifies clinically relevant subtypes of glioblastoma characterized
by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:
98-110.
31. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG
island methylator phenotype that defines a distinct subgroup of glioma.
Cancer Cell. 2010;17:510-522.
107